CVMP opinions on veterinary medicinal products

The Committee adopted a positive opinion for a marketing authorisation for Nobivac NXT HCPChFeLV, for the active immunisation of cats to reduce mortality, clinical signs and virus excretion caused by infection with feline herpesvirus type 1 (FHV); to reduce clinical signs and virus excretion caused by infection with feline calicivirus (FCV); to prevent mortality, clinical signs, leucopenia and virus excretion caused by infection with panleucopenia virus (FPL); to reduce the clinical signs and bacterial excretion caused by infection with Chlamydia felis, and to reduce persistent viraemia and clinical signs caused by feline leukaemia virus (FeLV). Nobivac NXT HCPChFeLV is the first veterinary vaccine recommended for authorisation in the EU that contains self-amplifying RNA packaged in a replication‑deficient replicon viral particle as an active substance.

The Committee adopted a positive opinion for a variation for Solensia to…